Beijing time at 22:38 on May 22, 2024onlinecasinonodepositbonus2022, Taihe Cheng Medical (CCMonlinecasinonodepositbonus2022.us) Stocks fluctuated, and the stock price fell sharply by 5.86%. As of press time, the stock was trading at US$0.612/share, with a trading volume of 135 shares, a turnover rate of 0.00%, and an amplitude of 0.00%.
Recent financial report data shows that the stock achieved operating income of US$75.85 million, net income of US$42.01 million, earnings per share of US$0.96, gross profit of US$10.81 million, and a P/E ratio of-0.64 times.
In terms of institutional ratings, there are currently no institutions making "buy, hold, sell" recommendations on the stock.
Among the medical facility industry where Taihecheng Medical shares are located, the overall increase was 0.02%. Among its related stocks, Newgenivf Group Limited C/Wts 03/04/2029(To Purr Com), American Oncology Network Inc C/Wts 20/09/2028(To Purr Com), Agilon Health, Inc. gained large gains, Assure Holdings Corp., American Oncology Network, Inc.、Novo Integrated Sciences, Inc. is relatively active, with turnover rates of 1.40%, 1.30%, and 1.16%, respectively. Related stocks with larger amplitudes include American Oncology Network Inc C/Wts 20/09/2028(To Purr Com), Newgenivf Group Limited C/Wts 03/04/2029(To Purr Com), Assure Holdings Corp., The amplitudes were 57.89%, 22.22%, and 20.04%, respectively.
About Taihecheng Medical Company: Taihecheng Medical Group Co., Ltd. operates a radiotherapy and diagnostic imaging center in China. The company has cooperation centers in multiple provinces and administrative regions in China. Its network includes radiotherapy centers and diagnostic imaging centers, as well as centers that provide other treatment and diagnostic services, such as electroencephalography for epilepsy diagnosis, hyperthermia to improve pain relief after radiotherapy and chemotherapy, high-intensity focused ultrasound for cancer treatment, stereotactic radio frequency ablation for Parkinson's disease and optometry and tonometer diagnosis of ophthalmic diseases.
{html}(The above content is Tencent's self-selected shares based on public information and intelligently generated by programs or algorithms. It is only used as a reference for users to watch the market, and is not used as investment advice or trading basis. The stock market is risky, please make decisions carefully.){html}